Top Industry Leaders in the Inhaled Corticosteroid Device Market
GlaxoSmithKline (GSK) and Innoviva's Trelegy Ellipta Approved for Chronic Obstructive Pulmonary Disease (COPD):ย This September 2023 milestone expands Trelegy Ellipta's reachย beyond asthma into COPD, a major market segment, potentially boosting GSK's market share
Teva Pharmaceuticals Launches Generic Version of AstraZeneca's Symbicort: This December 2023 development introduces a more affordable option for Symbicort, potentially increasing access to treatment for patients and impacting market dynamics.
Aptar Pharma & Tech Partners with Chiesi for Next-Generation Nebulizers: This January 2024 collaboration leverages Aptar's expertise in device design with Chiesi's respiratory medications, aiming to develop user-friendly and efficient nebulizers.
List ofย Inhaler Corticosteroid Deviceย Key companies in the market- Plumage Therapeutics LLP
- Pearl Therapeutic Inc
- Teijin LTD, Glaxoโs Advair
- LIYEN, Inc
- Amgen Inc
- Kos Pharmaceutical, Inc
- Teva Pharmaceutical.ย ย